An update on the diagnosis and treatment of vestibular schwannoma

References

• Smith MJ, Kulkarni A, Rustad C, et al. Vestibular schwannomas occur in schwannomatosis and should not be considered an exclusion criterion for clinical diagnosis. Am J Med Genet A. 2012;158A:215–219.
   PubMed Web of Science ®Google Scholar
• Hexter AT, Evans DG. The genetics of vestibular schwannoma. Curr Otorhinolaryngol Rep. 2014;2:226–234.
   Google Scholar
• Matthies C, Samii M. Management of 1000 vestibular schwannomas (acoustic neuromas): clinical presentation. Neurosurgery. 1997;40: 1–9. discussion 9–10.
   PubMed Web of Science ®Google Scholar
• Samii M, Matthies C. Management of 1000 vestibular schwannomas (acoustic neuromas): the facial nerve–preservation and restitution of function. Neurosurgery. 1997;40: 684–694. discussion 694–695.
   PubMed Web of Science ®Google Scholar
• Evans DGR, Moran A, King A, et al. Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: higher incidence than previously thought. Otol Neurotol Off Publ Am Otol Soc Am Neurotol Soc Eur Acad Otol Neurotol. 2005;26:93–97.
   PubMed Web of Science ®Google Scholar
• Babu R, Sharma R, Bagley JH, et al. Vestibular schwannomas in the modern era: epidemiology, treatment trends, and disparities in management: clinical article. J Neurosurg. 2013;119:121–130.
   PubMed Web of Science ®Google Scholar
• Lin D, Hegarty JL, Fischbein NJ, et al. The prevalence of “incidental” acoustic neuroma. Arch Otolaryngol Head Neck Surg. 2005;131:241–244.
   PubMedGoogle Scholar
• Shore-Freedman E, Abrahams C, Recant W, et al. Neurilemomas and salivary gland tumors of the head and neck following childhood irradiation. Cancer. 1983;51:2159–2163.
   PubMed Web of Science ®Google Scholar
• INTERPHONE Study Group. Acoustic neuroma risk in relation to mobile telephone use: results of the INTERPHONE international case-control study. Cancer Epidemiol. 2011;35:453–464.
   PubMed Web of Science ®Google Scholar
• Pellet W. History of vestibular schwannoma surgery. In Régis J, Roche P-H, editors. Prog. Neurol. Surg. [Internet]. Basel: KARGER; 2008. 6–23. [cited 2017 Sep 3]. Available from: http://www.karger.com/doi/10.1159/000156555
   Google Scholar
• Prasher DK, Tun T, Brookes GB, et al. Mechanisms of hearing loss in acoustic neuroma: an otoacoustic emission study. Acta Otolaryngol (Stockh). 1995;115:375–381.
   PubMed Web of Science ®Google Scholar
• Harcourt JP, Vijaya-Sekaran S, Loney E, et al. The incidence of symptoms consistent with cerebellopontine angle lesions in a general ENT out-patient clinic. J Laryngol Otol. 1999;113:518–522.
   PubMed Web of Science ®Google Scholar
• Nash R, Majithia A, Singh A. The agreement between protocols for the investigation of asymmetrical audiovestibular symptoms. J Int Adv Otol. 2016;12:98–100.
   PubMed Web of Science ®Google Scholar
• Doyle KJ. Is there still a role for auditory brainstem response audiometry in the diagnosis of acoustic neuroma? Arch. Otolaryngol Head Neck Surg (1979). 1999;125:232–234.
   Web of Science ®Google Scholar
• Marx SV, Langman AW, Crane RC. Accuracy of fast spin echo magnetic resonance imaging in the diagnosis of vestibular schwannoma. Am J Otolaryngol. 1999;20:211–216.
   PubMed Web of Science ®Google Scholar
• Smith MJ, Bowers NL, Bulman M, et al. Revisiting neurofibromatosis type 2 diagnostic criteria to exclude LZTR1-related schwannomatosis. Neurology. 2017;88:87–92.
   PubMed Web of Science ®Google Scholar
• Evans DG, Freeman S, Gokhale C, et al. Bilateral vestibular schwannomas in older patients: NF2 or chance? J Med Genet. 2015;52:422–424.
   PubMed Web of Science ®Google Scholar
• Evans DGR, Ramsden RT, Shenton A, et al. What are the implications in individuals with unilateral vestibular schwannoma and other neurogenic tumors? J Neurosurg. 2008;108:92–96.
   PubMed Web of Science ®Google Scholar
• Pathmanaban ON, Sadler KV, Kamaly-Asl ID, et al. Association of genetic predisposition with solitary schwannoma or meningioma in children and young adults. JAMA Neurol. 2017;74:1123.
   PubMed Web of Science ®Google Scholar
• Bakkouri WE, Kania RE, Guichard J-P, et al. Conservative management of 386 cases of unilateral vestibular schwannoma: tumor growth and consequences for treatment. J Neurosurg. 2009;110:662–669.
   PubMed Web of Science ®Google Scholar
• Suryanarayanan R, Ramsden RT, Saeed SR, et al. Vestibular schwannoma: role of conservative management. J Laryngol Otol. 2010;124:251–257.
   PubMed Web of Science ®Google Scholar
• Tschudi DC, Linder T, Fisch U. Conservative management of unilateral acoustic neuromas. Am J Otol. 2000;21:722–728.
   PubMedGoogle Scholar
• Ogawa K, Kanzaki J, Ogawa S, et al. The growth rate of acoustic neuromas. Acta Oto-Laryngol Suppl. 1991;487:157–163.
   PubMedGoogle Scholar
• Stangerup SE, Caye-Thomasen P, Tos M, et al. The natural history of vestibular schwannoma. Otology & Neurotology. 2006;27(4):547–552.
   PubMed Web of Science ®Google Scholar
• Sughrue ME, Yang I, Aranda D, et al. The natural history of untreated sporadic vestibular schwannomas: a comprehensive review of hearing outcomes. J Neurosurg. 2010;112:163–167.
   PubMed Web of Science ®Google Scholar
• Kano H, Kondziolka D, Khan A, et al. Predictors of hearing preservation after stereotactic radiosurgery for acoustic neuroma: clinical article. J Neurosurg. 2013;119 Suppl:863–873.
   PubMed Web of Science ®Google Scholar
• Cushing H. Tumors of the nervus acousticus and the syndrome of the cerebellopontine angle. Philadelphia: WB Saunders; 1917.
   Google Scholar
• Ramsden RT, Moffat DA. Intracanalicular acoustic neuromas: the case for early surgery. Clin Otolaryngol Allied Sci. 1994;19:1–2.
   PubMed Web of Science ®Google Scholar
• Setty P, D’Andrea K, Stucken E, et al. Endoscopic resection of vestibular schwannomas. J Neurol Surg Part B Skull Base. 2015;76:230–238.
   PubMed Web of Science ®Google Scholar
• Kumon Y, Kohno S, Ohue S, et al. Usefulness of endoscope-assisted microsurgery for removal of vestibular schwannomas. J Neurol Surg Part B Skull Base. 2012;73:042–047.
   PubMed Web of Science ®Google Scholar
• Copeland WR, Carlson ML, Neff BA, et al. Management of residual tumor after limited subtotal resection of large vestibular schwannomas: lessons learned and rationale for specialized care. World Neurosurg. 2017;105:737–744.
   PubMed Web of Science ®Google Scholar
• Nakatomi H, Jacob JT, Carlson ML, et al. Long-term risk of recurrence and regrowth after gross-total and subtotal resection of sporadic vestibular schwannoma. J Neurosurg. 2017;19:1–7.
   PubMedGoogle Scholar
• Chamoun R, MacDonald J, Shelton C, et al. Surgical approaches for resection of vestibular schwannomas: translabyrinthine, retrosigmoid, and middle fossa approaches. Neurosurg Focus. 2012;33:E9.
   PubMed Web of Science ®Google Scholar
• Driscoll CL, Jackler RK, Pitts LH, et al. Is the entire fundus of the internal auditory canal visible during the middle fossa approach for acoustic neuroma? Am. J Otol. 2000;21:382–388.
   PubMedGoogle Scholar
• Irving RM, Jackler RK, Pitts LH. Hearing preservation in patients undergoing vestibular schwannoma surgery: comparison of middle fossa and retrosigmoid approaches. J Neurosurg. 1998;88:840–845.
   PubMed Web of Science ®Google Scholar
• Youssef AS, Downes AE. Intraoperative neurophysiological monitoring in vestibular schwannoma surgery: advances and clinical implications. Neurosurg Focus. 2009;27:E9.
   PubMed Web of Science ®Google Scholar
• Strauss C, Romstöck J, Fahlbusch R, et al. Preservation of facial nerve function after postoperative vasoactive treatment in vestibular schwannoma surgery. Neurosurgery. 2006;59:577–584, discussion 577–584
   PubMed Web of Science ®Google Scholar
• Strauss C, Bischoff B, Neu M, et al. Vasoactive treatment for hearing preservation in acoustic neuroma surgery. J Neurosurg. 2001;95:771–777.
   PubMed Web of Science ®Google Scholar
• Scheller C, Wienke A, Tatagiba M, et al. Prophylactic nimodipine treatment for cochlear and facial nerve preservation after vestibular schwannoma surgery: a randomized multicenter Phase III trial. J Neurosurg. 2016;124:657–664.
   PubMed Web of Science ®Google Scholar
• Ansari SF, Terry C, Cohen-Gadol AA. Surgery for vestibular schwannomas: a systematic review of complications by approach. Neurosurg Focus. 2012;33:E14.
   PubMed Web of Science ®Google Scholar
• House JW, Brackmann DE. Facial nerve grading system. Otolaryngol.–Head Neck Surg Off J Am Acad Otolaryngol.–Head Neck Surg. 1985;93:146–147.
   PubMed Web of Science ®Google Scholar
• Sughrue ME, Yang I, Aranda D, et al. Beyond audiofacial morbidity after vestibular schwannoma surgery. J Neurosurg. 2011;114:367–374.
   PubMed Web of Science ®Google Scholar
• Bloch O, Sughrue ME, Kaur R, et al. Factors associated with preservation of facial nerve function after surgical resection of vestibular schwannoma. J Neurooncol. 2011;102:281–286.
   PubMed Web of Science ®Google Scholar
• Chen Z, Prasad SC, Di Lella F, et al. The behavior of residual tumors and facial nerve outcomes after incomplete excision of vestibular schwannomas: clinical article. J Neurosurg. 2014;120:1278–1287.
   PubMed Web of Science ®Google Scholar
• Mangus BD, Rivas A, Yoo MJ, et al. Management of cerebrospinal fluid leaks after vestibular schwannoma surgery. Otol Neurotol. 2011;32:1525–1529.
   PubMed Web of Science ®Google Scholar
• Falcioni M, Mulder JJ, Taibah A, et al. No cerebrospinal fluid leaks in translabyrinthine vestibular schwannoma removal: reappraisal of 200 consecutive patients. Am J Otol. 1999;20:660–666.
   PubMedGoogle Scholar
• Acoustic Neuroma Society. Headache associated with acoustic neuroma treatment [Internet]. 2012. [cited 2017 Jul 21]. Available from: http://acusticusneurinom.dk/wp-content/uploads/2015/10/booklet_-_headache.2012_-_final.pdf.
   Google Scholar
• Schmerber S, Palombi O, Boubagra K, et al. Long-term control of vestibular schwannoma after a translabyrinthine complete removal. Neurosurgery. 2005;57:693–698, discussion 693–698
   PubMed Web of Science ®Google Scholar
• Shelton C. Unilateral acoustic tumors: how often do they recur after translabyrinthine removal? The Laryngoscope. 1995;105:958–966.
   PubMed Web of Science ®Google Scholar
• Bennett ML, Jackson CG, Kaufmann R, et al. Postoperative imaging of vestibular schwannomas. Otolaryngol-Head Neck Surg. 2008;138:667–671.
   PubMed Web of Science ®Google Scholar
• Pritchard C, Clapham L, Davis A, et al. Psycho-socio-economic Outcomes In Acoustic Neuroma Patients And Their Carers Related To Tumour Size. Clin Otolaryngol. 2003;29:324–330.
   Google Scholar
• Casentini L, Fornezza U, Perini Z, et al. Multisession stereotactic radiosurgery for large vestibular schwannomas. J Neurosurg. 2015;122:818–824.
   PubMed Web of Science ®Google Scholar
• Apicella G, Paolini M, Deantonio L, et al. Radiotherapy for vestibular schwannoma: review of recent literature results. Rep Pract Oncol Radiother. 2016;21:399–406.
   PubMedGoogle Scholar
• Schwartz M. Stereotactic radiosurgery: comparing different technologies. CMAJ Can Med Assoc J J Assoc Medicale Can. 1998;158:625–628.
   PubMed Web of Science ®Google Scholar
• Murphy ES, Suh JH. Radiotherapy for vestibular schwannomas: a critical review. Int J Radiat Oncol Biol Phys. 2011;79:985–997.
   PubMed Web of Science ®Google Scholar
• Wise SC, Carlson ML, Tveiten ØV, et al. Surgical salvage of recurrent vestibular schwannoma following prior stereotactic radiosurgery. The Laryngoscope. 2016;126:2580–2586.
   PubMed Web of Science ®Google Scholar
• Marston AP, Jacob JT, Carlson ML, et al. Pretreatment growth rate as a predictor of tumor control following Gamma Knife radiosurgery for sporadic vestibular schwannoma. J Neurosurg. 2017;127:380–387.
   PubMed Web of Science ®Google Scholar
• Hasegawa T, Kida Y, Kato T, et al. Long-term safety and efficacy of stereotactic radiosurgery for vestibular schwannomas: evaluation of 440 patients more than 10 years after treatment with Gamma Knife surgery. J Neurosurg. 2013;118:557–565.
   PubMed Web of Science ®Google Scholar
• Carlson ML, Jacob JT, Pollock BE, et al. Long-term hearing outcomes following stereotactic radiosurgery for vestibular schwannoma: patterns of hearing loss and variables influencing audiometric decline. J Neurosurg. 2013;118:579–587.
   PubMed Web of Science ®Google Scholar
• Wolbers JG, Dallenga AH, Mendez Romero A, et al. What intervention is best practice for vestibular schwannomas? A systematic review of controlled studies. BMJ Open. 2013;3:2.
   Google Scholar
• Hayhurst C, Zadeh G. Tumor pseudoprogression following radiosurgery for vestibular schwannoma. Neuro-Oncol. 2012;14:87–92.
   PubMed Web of Science ®Google Scholar
• Pollock BE, Link MJ, Stafford SL, et al. The risk of radiation-induced tumors or malignant transformation after single-fraction intracranial radiosurgery: results based on a 25-year experience. Int J Radiat Oncol Biol Phys. 2017;97:919–923.
   PubMed Web of Science ®Google Scholar
• Hansasuta A, Choi CYH, Gibbs IC, et al. Multisession stereotactic radiosurgery for vestibular schwannomas: single-institution experience with 383 cases. Neurosurgery. 2011;69:1200–1209.
   PubMed Web of Science ®Google Scholar
• Persson O, Bartek J, Shalom NB, et al. Stereotactic radiosurgery vs. fractionated radiotherapy for tumor control in vestibular schwannoma patients: a systematic review. Acta Neurochir (Wien). 2017;159:1013–1021.
   PubMed Web of Science ®Google Scholar
• Weber DC, Chan AW, Bussiere MR, et al. Proton beam radiosurgery for vestibular schwannoma: tumor control and cranial nerve toxicity. Neurosurgery. 2003;53:577–586, discussion 586–588
   PubMed Web of Science ®Google Scholar
• Baser ME, Friedman JM, Aeschliman D, et al. Predictors of the risk of mortality in neurofibromatosis 2. Am J Hum Genet. 2002;71:715–723.
   PubMed Web of Science ®Google Scholar
• Lloyd SKW, King AT, Rutherford SA, et al. Hearing optimisation in neurofibromatosis type 2: a systematic review. Clin Otolaryngol Off J ENT-UK Off J Neth Soc Oto-Rhino-Laryngol Cervico-Facial Surg. 2017.
   Google Scholar
• Evans DGR. Neurofibromatosis 2 [Bilateral acoustic neurofibromatosis, central neurofibromatosis, NF2, neurofibromatosis type II]. Genet Med Off J Am Coll Med Genet. 2009;11:599–610.
   Google Scholar
• Sobel RA. Vestibular (acoustic) schwannomas: histologic features in neurofibromatosis 2 and in unilateral cases. J Neuropathol Exp Neurol. 1993;52:106–113.
   PubMed Web of Science ®Google Scholar
• Jääskeläinen J, Paetau A, Pyykkö I, et al. Interface between the facial nerve and large acoustic neurinomas. Immunohistochemical study of the cleavage plane in NF2 and non-NF2 cases. J Neurosurg. 1994;80:541–547.
   PubMed Web of Science ®Google Scholar
• Moffat DA, Lloyd SKW, Macfarlane R, et al. Outcome of translabyrinthine surgery for vestibular schwannoma in neurofibromatosis type 2. Br J Neurosurg. 2013;27:446–453.
   PubMed Web of Science ®Google Scholar
• Mathieu D, Kondziolka D, Flickinger JC, et al. Stereotactic radiosurgery for vestibular schwannomas in patients with neurofibromatosis type 2: an analysis of tumor control, complications, and hearing preservation rates. Neurosurgery. 2007;60:460–468, discussion 468–470
   PubMed Web of Science ®Google Scholar
• Rowe J, Radatz M, Kemeny A. Radiosurgery for type II neurofibromatosis. In Régis J, Roche P-H, editors. Prog. Neurol. Surg. [Internet]. Basel: KARGER; 2008. 176–182. [cited 2017 Sep 11]. Available from: http://www.karger.com/doi/10.1159/000156907
   Google Scholar
• Evans DGR, Birch JM, Ramsden RT, et al. Malignant transformation and new primary tumors after therapeutic radiation for benign disease: substantial risks in certain tumor prone syndromes. J Med Genet. 2006;43:289–294.
   PubMed Web of Science ®Google Scholar
• Carlson ML, Babovic-Vuksanovic D, Messiaen L, et al. Radiation-induced rhabdomyosarcoma of the brainstem in a patient with neurofibromatosis type 2. J Neurosurg. 2010;112:81–87.
   PubMed Web of Science ®Google Scholar
• Evans DGR, Baser ME, O’Reilly B, et al. Management of the patient and family with neurofibromatosis 2: a consensus conference statement. Br J Neurosurg. 2005;19:5–12.
   PubMed Web of Science ®Google Scholar
• Plotkin SR, Stemmer-Rachamimov AO, Barker FG, et al. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med. 2009;361:358–367.
   PubMed Web of Science ®Google Scholar
• Plotkin SR, Merker VL, Halpin C, et al. Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients. Otol Neurotol Off Publ Am Otol Soc Am Neurotol Soc Eur Acad Otol Neurotol. 2012;33:1046–1052.
   PubMed Web of Science ®Google Scholar
• The Neuro Foundation. Bevacizumab (Avastin) in NF2 [Internet]. [cited 2017 Jul 28]. Available from: https://www.nfauk.org/what-is-neurofibromatosis/nf-type-2/test/.
   Google Scholar
• Morris KA, Golding JF, Axon PR, et al. Bevacizumab in neurofibromatosis type 2 (NF2) related vestibular schwannomas: a nationally coordinated approach to delivery and prospective evaluation. Neuro-Oncol Pract. 2016;3:281–289.
   Google Scholar
• Morris KA, Golding JF, Blesing C, et al. Toxicity profile of bevacizumab in the UK Neurofibromatosis type 2 cohort. J Neurooncol. 2017;131:117–124.
   PubMed Web of Science ®Google Scholar
• Evans DG, Kalamarides M, Hunter-Schaedle K, et al. Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2. Clin Cancer Res Off J Am Assoc Cancer Res. 2009;15:5032–5039.
   PubMed Web of Science ®Google Scholar
• James MF, Han S, Polizzano C, et al. NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth. Mol Cell Biol. 2009;29:4250–4261.
   PubMed Web of Science ®Google Scholar
• Lane HA, Wood JM, McSheehy PMJ, et al. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. Clin Cancer Res Off J Am Assoc Cancer Res. 2009;15:1612–1622.
   PubMed Web of Science ®Google Scholar
• Karajannis MA, Legault G, Hagiwara M, et al. Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas. Neuro-Oncol. 2014;16:292–297.
   PubMed Web of Science ®Google Scholar
• Goutagny S, Raymond E, Esposito-Farese M, et al. Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas. J Neurooncol. 2015;122:313–320.
   PubMed Web of Science ®Google Scholar
• Karajannis MA, Legault G, Hagiwara M, et al. Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas. Neuro-Oncol. 2012;14:1163–1170.
   PubMed Web of Science ®Google Scholar
• Ammoun S, Cunliffe CH, Allen JC, et al. ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma. Neuro-Oncol. 2010;12:834–843.
   PubMed Web of Science ®Google Scholar
• NHS England. Transforming participation in health and care. [Internet]. 2013 [cited 2015 Sep 17]. Available from: www.england.nhs.uk/wp-content/uploads/2013/09/trans-part-hc-guid1. pdf.
   Google Scholar
• Carlson ML, Tveiten OV, Driscoll CL, et al. Long-term quality of life in patients with vestibular schwannoma: an international multicenter cross-sectional study comparing microsurgery, stereotactic radiosurgery, observation, and nontumor controls. J Neurosurg. 2015;122:833–842.
   PubMed Web of Science ®Google Scholar
• MacKeith S, Kerr R, Milford C. Trends in acoustic neuroma management: a 20-year review of the oxford skull base clinic. J Neurol Surg Part B Skull Base. 2013;74:194–200.
   PubMed Web of Science ®Google Scholar